Brand driven innovation focuses on the symbiosis between branding, innovation, and design. It uses the brand to drive innovation, innovation to fulfill the brand's promise, and design to connect experiences. Examples are provided of using this approach with clients like Nike, Sissy Boy, Nlisis, and Mexx. For Nlisis, a brand guide and design language were developed from research to establish a coherent brand experience across all touchpoints.
Michael Dake, MD has financial interests in several medical device companies including W. L. Gore, Cook Medical, NovoStent, Vatrix, Amaranth, CVRx, Endoluminl Sciences, REVA Medical, and TriVascular. He also serves as an officer or director for VIVA Physicians Group.
The document describes a prospective, randomized trial comparing the Zilver PTX drug-eluting stent to percutaneous transluminal angioplasty (PTA) and provisional bare metal stenting for treating symptomatic femoropopliteal peripheral artery disease. At 12 months, primary patency was significantly higher for patients receiving the Zilver PTX stent compared to
In service innovation projects complexities abound, both within the boundaries of the organization and outside of them: value chains have become value networks, target customers have contextual and situational preferences in their complex experience journeys, and interactions with the organization involve many channels and touch points. Customer centricity is a prerequisite but it requires various cross sections through the organization to cooperate smoothly.
In his keynote, Erik will discuss the glue that holds these complex processes together. On the basis of case studies from his service design consulting practice, and insights from his teaching at the Delft University of Technology, Erik will dive deeper into how to align various enterprise functions around a shared and actionable vision and towards a coherent and tangible end-result. He will show through analysis of these various cases that a shared, actionable, and congruent enterprise vision is of vital importance for innovation success, and can be steered and managed effectively.
Brand driven innovation focuses on the symbiosis between branding, innovation, and design. It uses the brand to drive innovation, innovation to fulfill the brand's promise, and design to connect experiences. Examples are provided of using this approach with clients like Nike, Sissy Boy, Nlisis, and Mexx. For Nlisis, a brand guide and design language were developed from research to establish a coherent brand experience across all touchpoints.
Michael Dake, MD has financial interests in several medical device companies including W. L. Gore, Cook Medical, NovoStent, Vatrix, Amaranth, CVRx, Endoluminl Sciences, REVA Medical, and TriVascular. He also serves as an officer or director for VIVA Physicians Group.
The document describes a prospective, randomized trial comparing the Zilver PTX drug-eluting stent to percutaneous transluminal angioplasty (PTA) and provisional bare metal stenting for treating symptomatic femoropopliteal peripheral artery disease. At 12 months, primary patency was significantly higher for patients receiving the Zilver PTX stent compared to
In service innovation projects complexities abound, both within the boundaries of the organization and outside of them: value chains have become value networks, target customers have contextual and situational preferences in their complex experience journeys, and interactions with the organization involve many channels and touch points. Customer centricity is a prerequisite but it requires various cross sections through the organization to cooperate smoothly.
In his keynote, Erik will discuss the glue that holds these complex processes together. On the basis of case studies from his service design consulting practice, and insights from his teaching at the Delft University of Technology, Erik will dive deeper into how to align various enterprise functions around a shared and actionable vision and towards a coherent and tangible end-result. He will show through analysis of these various cases that a shared, actionable, and congruent enterprise vision is of vital importance for innovation success, and can be steered and managed effectively.
Health and fitness apps and devices collect users' personal data, but it is unclear how user data is monetized and who earns from it. A proposed solution is a personal health record platform with an open app store that crowd-sources app development and takes a percentage of app store revenues, while providing platform-level privacy and easy data access. This could form the basis of a new business model for personal health and healthcare data.
This document discusses using ELISA without washing steps by developing a switchable reporter enzyme system. It describes tuning a beta-lactamase enzyme and its inhibitor protein to have high affinity binding and then using this system for wash-free ELISA assays. The goal is to create assays that are faster and require less hands-on time by eliminating washing steps traditionally required in ELISA.
Jack Schalken has co-founded two companies - NovioGendix in 2006 and Oncodrone in 2013 - to translate his translational research into clinical applications and products. As an "entrepreneurial scientist", he learned important lessons about negotiating terms with his academic institution, building a management team, securing financing, and acquiring business skills to successfully launch and grow these ventures. Both companies have worked to bridge the gap between research and clinical validation or product development for cancer diagnostics and therapeutics.
Health and fitness apps and devices collect users' personal data, but it is unclear how user data is monetized and who earns from it. A proposed solution is a personal health record platform with an open app store that crowd-sources app development and takes a percentage of app store revenues, while providing platform-level privacy and easy data access. This could form the basis of a new business model for personal health and healthcare data.
This document discusses using ELISA without washing steps by developing a switchable reporter enzyme system. It describes tuning a beta-lactamase enzyme and its inhibitor protein to have high affinity binding and then using this system for wash-free ELISA assays. The goal is to create assays that are faster and require less hands-on time by eliminating washing steps traditionally required in ELISA.
Jack Schalken has co-founded two companies - NovioGendix in 2006 and Oncodrone in 2013 - to translate his translational research into clinical applications and products. As an "entrepreneurial scientist", he learned important lessons about negotiating terms with his academic institution, building a management team, securing financing, and acquiring business skills to successfully launch and grow these ventures. Both companies have worked to bridge the gap between research and clinical validation or product development for cancer diagnostics and therapeutics.